{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05954312",
            "orgStudyIdInfo": {
                "id": "VVD-130037-001"
            },
            "organization": {
                "fullName": "Vividion Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors",
            "officialTitle": "A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-first-in-human-fih-study-to-evaluate-the-safety-and-tolerability-of-vvd-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-12",
            "studyFirstSubmitQcDate": "2023-07-12",
            "studyFirstPostDateStruct": {
                "date": "2023-07-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vividion Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A FIH study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VVD-130037 in participants with advanced solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumors"
            ],
            "keywords": [
                "VVD-130037",
                "First-in-Human",
                "KEAP1",
                "NRF2",
                "Cancer",
                "small molecule",
                "squamous cell histology",
                "esophageal adenocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "VVD-130037 Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ascending doses of VVD-130037, orally, once daily in 21-day treatment cycles.",
                    "interventionNames": [
                        "Drug: VVD-130037"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "VVD-130037",
                    "description": "Oral tablets",
                    "armGroupLabels": [
                        "VVD-130037 Dose Escalation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and Severity of Dose-limiting Toxicities (DLTs) During DLT Observation Period",
                    "description": "Incidence and severity of DLTs will be assessed per DLT criteria set forth in the protocol based on adverse events (AEs) evaluated per National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.",
                    "timeFrame": "From Day 1 to Day 21 of Cycle 1 [cycle length=21 days]"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of Participants With AEs, Serious Adverse Events (SAEs), and Clinical Laboratory Abnormalities",
                    "timeFrame": "From the administration of first dose through 30 days after last study drug administration or start of subsequent therapy (up to approximately 4 years)"
                },
                {
                    "measure": "Area Under the Plasma Concentration-time Curve (AUC) of VVD-130037",
                    "timeFrame": "Predose and multiple timepoints post-dose from Cycle 1 Day 1 up to Cycle 5 Day 1 (cycle length=21 days)"
                },
                {
                    "measure": "Maximum Observed Concentration (Cmax) of VVD-130037",
                    "timeFrame": "Predose and multiple timepoints post-dose from Cycle 1 Day 1 up to Cycle 5 Day 1 (cycle length=21 days)"
                },
                {
                    "measure": "Apparent Terminal Half-life (T1/2) of VVD-130037",
                    "timeFrame": "Predose and multiple timepoints post-dose from Cycle 1 Day 1 up to Cycle 5 Day 1 (cycle length=21 days)"
                },
                {
                    "measure": "QT/Corrected QT (QTc) Interval and Other Electrocardiogram (ECG) Parameters",
                    "description": "Number of participants with changes in QT/QTc interval and other ECG parameters will be assessed.",
                    "timeFrame": "Up to end of treatment (up to approximately 4 years)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Histologically or cytologically confirmed metastatic or unresectable solid tumor.\n* Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by the Investigator.\n* Have progressed on or after all prior standard-of-care therapies for metastatic disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status \u22641.\n* Adequate organ and marrow function as defined in the protocol.\n\nKey Exclusion Criteria:\n\n* Participant is known to have a mutation that has no expectation of benefit from VVD-130037. Current such mutations include the following:\n\n  1. KEAP1 nonsense mutation (any position)\n  2. KEAP1 frameshift mutation (any position)\n* Any unresolved toxicity Grade \u22652 per CTCAE version 5.0 from previous anticancer treatment.\n* Current or prior treatment with anti-epileptic medications for the treatment or prophylaxis of seizures.\n* History of seizure or condition that may predispose to seizure.\n* History or presence of central nervous system (CNS) metastases or spinal cord compression.\n* Uncontrolled arterial hypertension despite optimal medical management.\n* Risk factors for abnormal heart rhythm/QT prolongation as defined in the protocol.\n* History of the following cardiac diseases:\n\n  i) congestive heart failure (New York Heart Association \\[NYHA\\] Class \\>II), ii) unstable angina, iii) new onset angina within past 6 months, iv) myocardial Infarction within the past 6 months, v) clinically significant arrhythmias within past 6 months.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Vividion Clinical Trial Call Center",
                    "role": "CONTACT",
                    "phone": "(858) 345-9752",
                    "email": "clinicaltrials@vividion.com"
                }
            ],
            "locations": [
                {
                    "facility": "Florida Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Sarasota",
                    "state": "Florida",
                    "zip": "34232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.33643,
                        "lon": -82.53065
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "MDACC",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Dallas",
                    "status": "RECRUITING",
                    "city": "Irving",
                    "state": "Texas",
                    "zip": "75039",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.81402,
                        "lon": -96.94889
                    }
                },
                {
                    "facility": "NEXT Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "START Barcelona Hospital HM Nou Delfos",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "NEXT Madrid",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "START Madrid CIOCC",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Start Madrid-FJD, Hospital Fundacion Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}